R. Engelhardt

1000 total citations
33 papers, 767 citations indexed

About

R. Engelhardt is a scholar working on Oncology, Biomedical Engineering and Molecular Biology. According to data from OpenAlex, R. Engelhardt has authored 33 papers receiving a total of 767 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Biomedical Engineering and 7 papers in Molecular Biology. Recurrent topics in R. Engelhardt's work include Cancer, Stress, Anesthesia, and Immune Response (5 papers), Nanoplatforms for cancer theranostics (5 papers) and Cancer Research and Treatments (4 papers). R. Engelhardt is often cited by papers focused on Cancer, Stress, Anesthesia, and Immune Response (5 papers), Nanoplatforms for cancer theranostics (5 papers) and Cancer Research and Treatments (4 papers). R. Engelhardt collaborates with scholars based in Germany, Canada and Japan. R. Engelhardt's co-authors include Chris Galanos, Andréas Mackensen, E. Thiel, Th. Büchner, D. Urbanitz, H. Löffler, P. Koch, H. Heimpel, H. Bodenstein and D. Hoelzer and has published in prestigious journals such as Blood, The Journal of Immunology and Annals of Oncology.

In The Last Decade

R. Engelhardt

32 papers receiving 722 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Engelhardt Germany 13 250 186 176 169 148 33 767
Michael S. Kennedy United States 10 224 0.9× 113 0.6× 50 0.3× 247 1.5× 130 0.9× 14 916
Mark Van Oene Canada 9 297 1.2× 187 1.0× 51 0.3× 112 0.7× 292 2.0× 9 1.3k
Sven-Åge Killmann Denmark 16 173 0.7× 136 0.7× 72 0.4× 288 1.7× 145 1.0× 37 811
Shringi Sharma United States 14 100 0.4× 124 0.7× 101 0.6× 84 0.5× 233 1.6× 48 884
G Hamilton Canada 12 233 0.9× 234 1.3× 92 0.5× 27 0.2× 234 1.6× 28 850
Masakatsu Yanagimachi Japan 14 196 0.8× 99 0.5× 73 0.4× 171 1.0× 155 1.0× 37 561
Alan M. Miller United States 15 109 0.4× 155 0.8× 46 0.3× 95 0.6× 98 0.7× 34 546
Terukazu Tanaka Japan 14 95 0.4× 144 0.8× 34 0.2× 92 0.5× 184 1.2× 50 554
M. Fukushima Japan 6 187 0.7× 164 0.9× 37 0.2× 92 0.5× 130 0.9× 17 611
Fangping Chen China 19 406 1.6× 155 0.8× 98 0.6× 142 0.8× 690 4.7× 50 1.3k

Countries citing papers authored by R. Engelhardt

Since Specialization
Citations

This map shows the geographic impact of R. Engelhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Engelhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Engelhardt more than expected).

Fields of papers citing papers by R. Engelhardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Engelhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Engelhardt. The network helps show where R. Engelhardt may publish in the future.

Co-authorship network of co-authors of R. Engelhardt

This figure shows the co-authorship network connecting the top 25 collaborators of R. Engelhardt. A scholar is included among the top collaborators of R. Engelhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Engelhardt. R. Engelhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fetscher, Sebastian, Wolfram Brugger, R. Engelhardt, et al.. (1999). Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report. Annals of Oncology. 10(5). 561–568. 19 indexed citations
2.
Fetscher, Sebastian, Wolfram Brugger, R. Engelhardt, et al.. (1997). Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. Annals of Oncology. 8(1). 49–56. 35 indexed citations
3.
Ochs, A., Dietmar Berger, R Mertelsmann, et al.. (1997). The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Annals of Oncology. 8(2). 200–202. 17 indexed citations
4.
Fetscher, Sebastian, Jürgen Finke, R. Engelhardt, Roland Mertelsmann, & W. Lange. (1997). Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Annals of Hematology. 74(2). 73–77. 10 indexed citations
5.
Otto, F, Peter Schmid, Andréas Mackensen, et al.. (1996). Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. European Journal of Cancer. 32(10). 1712–1718. 82 indexed citations
6.
Fuhr, Uwe, Karl Ludwig Rost, R. Engelhardt, et al.. (1996). Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics. 6(2). 159–176. 98 indexed citations
7.
Stern, A., R. Engelhardt, C. Stephen Foster, et al.. (1995). SDZ MRL 953, a lipid A analog as selective cytokine inducer.. PubMed. 392. 549–65. 5 indexed citations
8.
Engelhardt, R., F. Otto, Andréas Mackensen, R Mertelsmann, & Chris Galanos. (1995). Endotoxin (Salmonella abortus equi) in cancer patients. Clinical and immunological findings.. PubMed. 392. 253–61. 20 indexed citations
9.
Brugger, W., R. Engelhardt, R Mertelsmann, & Lothar Kanz. (1994). The management of primary mediastinal B-cell lymphoma with sclerosis. Annals of Oncology. 5(10). 943–947. 4 indexed citations
10.
Pruzanski, W., Andréas Mackensen, R. Engelhardt, E. Stefanski, & Peter Vadas. (1992). Induction of Circulating Phospholipase A2 Activity by Intravenous Infusion of Endotoxin in Patients with Neoplasia. Journal of Immunotherapy. 12(4). 242–246. 14 indexed citations
11.
Mackensen, Andréas, Chris Galanos, & R. Engelhardt. (1991). Modulating activity of interferon-gamma on endotoxin-induced cytokine production in cancer patients. Blood. 78(12). 3254–3258. 1 indexed citations
12.
Köchling, Georg, et al.. (1988). Plasmablastic immunoglobulin-secreting lymphoma. Journal of Molecular Medicine. 66(19). 990–994. 1 indexed citations
13.
Hinkelbein, W., et al.. (1988). Toxic Effects of Irradiation or Doxorubicin in Combination with Moderate Whole-Body Hyperthermia on Bone Marrow in Rats. Recent results in cancer research. 109. 71–82. 3 indexed citations
14.
Yamada, Kiyoshi, et al.. (1988). A Rapid in Vitro Assay for Predicting Thermochemosensitivity of Human Cancer: Comparison with Clonogenic Assay. Recent results in cancer research. 107. 177–183. 1 indexed citations
15.
Yamada, Kiyoshi, et al.. (1988). Predicting the Sensitivity of Human Cancers to Combined Chemotherapy and Hyperthermia. Recent results in cancer research. 109. 250–257. 2 indexed citations
16.
Henke, Michael, et al.. (1986). Successful therapy of sarcoidosis-associated thrombocytopenia refractory to corticosteroids by a single course of human gammaglobulins. Journal of Molecular Medicine. 64(22). 1209–1211. 5 indexed citations
17.
Engelhardt, R.. (1986). Clinical Requirements of Local and Regional Hyperthermia Application. Recent results in cancer research. 101. 1–6. 1 indexed citations
18.
Neumann, H., et al.. (1986). Comparison of bleomycin and peplomycin toxicity on clonogenic tumor cells from various human tumors. Journal of Cancer Research and Clinical Oncology. 112(2). 165–169. 2 indexed citations
19.
Fiebig, Heinz‐Herbert, H. Henß, R. Engelhardt, et al.. (1983). Phase-II-Studie von AMSA bei Erwachsenen mit therapierefraktären akuten Leukämien. Oncology Research and Treatment. 6(4). 188–190. 2 indexed citations
20.
Engelhardt, R., et al.. (1979). Variante des von Willebrand-J�rgens-Syndroms mit Ver�nderung des Faktor VIII/von Willebrand Faktor Proteins. Annals of Hematology. 38(1). 25–34. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael S. Kennedy Breakdown of academic impact, for papers by Mark Van Oene Breakdown of academic impact, for papers by Sven-Åge Killmann Breakdown of academic impact, for papers by Shringi Sharma Breakdown of academic impact, for papers by G Hamilton Breakdown of academic impact, for papers by Masakatsu Yanagimachi Breakdown of academic impact, for papers by Alan M. Miller Breakdown of academic impact, for papers by Terukazu Tanaka Breakdown of academic impact, for papers by M. Fukushima Breakdown of academic impact, for papers by Fangping Chen
Rankless by CCL
2026